Lexie Farrar’s Post

It is a tough reality that the vast majority of clinical candidates fail. In our latest blog, I explore this topic a little more freely and am interested to hear your thoughts. What should we be doing differently and how should we be approaching future drug development?

𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲: 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 📚 - https://lnkd.in/dyA8JyT6 Cancer is characterized as uncontrolled development of unusual cells. Current therapy systems for disease incorporate blend of radiation, chemotherapy, and medical procedure. The drawn out utility of traditional drug delivery systems for malignant cells growth chemotherapy may harm ordinary multiplying cells, and thus is specifically utilized for the administration of most extreme tumors. 👉 𝐓𝐨𝐩 𝐈𝐦𝐩𝐚𝐜𝐭𝐢𝐧𝐠 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 - 🔰 Rise in incidents of cancer around the globe coupled with rise in the awareness about electie treatment techniques is anticipated to boost market growth for drug deliery systems. 🔰 Furthermore, utilization of nanoparticles to treat diseases in arious countries is anticipated to support market deelopment. 🔰 Increase in the number of key major players in the market who are expanding their interest in research and deelopment of drug deliery system coupled with growing product portfolio and administratie endorsements are anticipated to further propel market growth. Drug delivery in cancer involves the targeted administration of therapeutic agents to cancerous #cells while minimizing damage to healthy tissues. This approach aims to enhance treatment efficacy and reduce #sideeffects associated with conventional chemotherapy. Various innovative techniques, such as nanoparticle-based drug carriers, liposomes, and antibody-drug conjugates, enable precise targeting of #cancer cells. Additionally, advancements in #nanotechnology and biomaterials have led to the development of novel delivery systems capable of overcoming #biological barriers and improving #drug bioavailability. 💊 𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 - Merck Group, Eli Lilly and Company, Genentech, Novartis, GSK, Pfizer, Sanofi, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb Co. #cancertreatment #pharmaceuticals #pharma #drugs #drugdelivery 📚 𝐃𝐨𝐧'𝐭 𝐌𝐢𝐬𝐬 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐓𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dyA8JyT6

One treatment for postmenopausal breast cancer patients is aromatase inhibitors. Unfortunately, they often have debilitating side effects. Luckily, the City of Hope and Biopharmaceutical Research Company (BRC) kicked off a clinical trial to learn how cannabinoids might help. ( Biomedical research funding ) typically comes from various sources, including government grants, private foundations, nonprofit organizations, and corporate investments. In the case of BRC (Biomedical Research Center), funding may come from a combination of: 1. **Government Agencies**: Such as the National Institutes of Health (NIH) in the U.S., which provides significant funding for biomedical research projects. 2. **Private Corporations**: Pharmaceutical and biotech companies often invest in biomedical research to develop new drugs and therapies. 3. **Philanthropic Organizations**: Foundations and nonprofit entities dedicated to health and medical research may provide grants to support innovative studies. 4. **Academic Institutions**: Many universities have internal funding mechanisms or partnerships that support research initiatives. 5. **Crowdfunding**: Increasingly, researchers are turning to platforms that allow the public to contribute to specific research projects. If you have a specific BRC you’re referring to, please provide more details for tailored information about its funding sources.

Why aren't drug approval rates improving over time? The average failure rate of a therapeutic is 90%. This number exponentially increases in oncology, where only 1 in 10,000 preclinical candidates make it to drug approval. In our latest blog, Nicholas Woudberg explores the limited success of clinical development and what the pharma and biotech industry can do to address it. https://lnkd.in/ef8DuZRx

𝗔 𝐔𝐥𝐭𝐢𝐦𝐚𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐋𝐢𝐯𝐞𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 @  https://lnkd.in/gDee2gVv The Liver Cancer Therapeutics Market was valued at USD 3,625.43 million in 2023 and is projected to reach USD 15,903.20 million by 2031, growing at a compound annual growth rate (CAGR) of 20.3% from 2024 to 2031. The Liver Cancer Therapeutics Market is witnessing rapid growth, propelled by rising incidences of liver cancer globally and advancements in therapeutic options. Innovations in targeted therapies, immunotherapies, and combination treatments are significantly enhancing patient outcomes, driving market expansion. Increased awareness and early diagnosis, coupled with substantial investments in research and development, are also contributing to this growth. Moreover, regulatory approvals for new drugs and treatments are accelerating the availability of advanced therapies. As healthcare providers strive to improve survival rates and quality of life for liver cancer patients, the demand for effective and innovative therapeutic solutions continues to rise, positioning the market for robust growth in the coming years. 𝐓𝐡𝐞 𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬  Imclone Systems Incorporated .,  Alnylam Pharmaceuticals .,  F. Hoffmann-La Roche Ltd., Onyx Pharmaceuticals, Inc., an Amgen subsidiary ., ArQule U.K. Ltd a Co ,  Pfizer ., Celsion Corporation Corp., Jennere Biotherapeutics Inc., 4SC AG,  Bayer Schering Pharma,  and other players. #ImCloneSystems #AlnylamPharmaceuticals #Roche #OnyxPharmaceuticals #ArQule #Pfizer #Celsion #JennereBiotherapeutics #4SC #BayerScheringPharma #Biotech #Pharma #CancerResearch #DrugDevelopment #Pharmaceuticals #Biopharma #HealthcareInnovation #MedicalResearch #LiverCancerTherapeutics #ClinicalTrials #LiverCancer #CancerTherapeutics #LiverCancerTreatment #Oncology #CancerResearch #Immunotherapy #TargetedTherapy #MedicalInnovation #PharmaIndustry #Biotech #Healthcare #CancerCare #ClinicalTrials #DrugDevelopment #PrecisionMedicine #CancerSurvivorship #HealthTech #Pharmaceuticals #Hepatology #CancerAwareness

Exciting News! 🌟 We are thrilled to announce that SATHGEN THERAPEUTICS has been granted an Indian Patent (No. 528187) for their groundbreaking technological innovation titled 'PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME'. This innovative collaboration among SATHGEN THERAPEUTICS, DelNova Healthcare - Formulation Partner For Generic and Complex Generics Formulation and Institute Of Chemical Technology led to the development of a novel formulation designed for a clinical candidate for combating Triple Negative Breast Cancer. This patent marks a significant milestone in our journey towards revolutionizing cancer treatment. The novel formulation, developed using cutting-edge technology, promises to enhance the effectiveness and safety of treatments for one of the most challenging forms of cancer. We extend our heartfelt congratulations to all the researchers, scientists, and team members who have played a crucial role in this achievement. This success not only underscores our commitment to pioneering healthcare solutions but also reinforces our dedication to making a tangible difference in the lives of patients around the globe. Stay tuned for more updates as we continue to advance in our mission to fight cancer with innovative solutions. Samir Somaiya, Dr. Sangeeta Srivastava, Sendurai Mani, Dr. Maithili Athavale Vijayendrakumar Redasani Shweta Redasani #InnovationInHealthcare #CancerResearch #Biotechnology #Pharmaceuticals #PatentGranted #TripleNegativeBreastCancer #CollaborationForACure #science #research #technology #formulation #pharmacy #India

Indeed it’s Great News!! It’s perfect example of collaborative work between multidisciplinary teams under one vision of Samir Somaiya. The efforts and bounce back attitude with never give up approach of Prashant Kharkar supported by SATHGEN THERAPEUTICS team Dr. Sangeeta Srivastava Dr. Maithili Athavale which taken forward by Dr Deepa Arora MBBS, MD and well executed by DelNova Healthcare - Formulation Partner For Generic and Complex Generics Formulation resulted in fast track grant of Innovation PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME'. It’s one of the rewarding milestone where world see towards India as #InnovationCentre for Patient care, specifically in cancer treatment. This patent marks a significant milestone in our journey towards making “Innovative and Differtiated Formulations” for revolutionizing treatment. The novel formulation, developed using cutting-edge Green technology and contineous process further marked our responsibility towards providing #safeenviornment . We extend our heartfelt congratulations to all the Team members, researchers, scientists and well wishes across industry who been instrumental in making this happen. This achievement is one step more closer towards #ReducingBurdenOfHealthcare” Thanks Samir Somaiya Dr. Sangeeta Srivastava Prashant Kharkar Shweta Redasani Entire DelNova Healthcare - Formulation Partner For Generic and Complex Generics Formulation Team To be part of this journey and motivating us. #InnovationInHealthcare #CancerResearch #Biotechnology #Pharmaceuticals #PatentGranted #TripleNegativeBreastCancer #CollaborationForACure #science #research #technology #formulation #Hotmeltextrusion #pharmacy #India

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for NI&I indications, filed on Friday with the SEC to raise up to $150 million in an initial public offering. Contineum Therapeutics is focused on discovering and developing novel, oral small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The company has completed a Phase 1 trial of PIPE-791 in healthy volunteers in both indications, and it plans to submit a Clinical Trial Authorization to the Medicines and Healthcare products Regulatory Agency to commence a Phase 1b open-label trial in 2024. Contineum is collaborating with Johnson & Johnson on its second candidate, PIPE-307, which has entered a Phase 2 trial in relapse remitting MS. #biotech #biotechnology #capitalmarket #capitalraise #ipos #initialpublicoffering #therapeutics #moleculetherapies #sec #healthcare

Stories making headlines today in the biopharma industry: Pfizer has announced its decision to shut down its Boulder, Colorado research facility by Q2 2024. This resolution comes despite investor interest, and unfortunately, many employees face job cuts. This facility was acquired as a part of Arrays BioPharm Cellares' acquisition in 2019. Meanwhile, cell therapy manufacturer Cellares enters the global market with its first deal inked with Bristol Myers Squibb. The agreement, worth $380 million, offers Bristol Myers access to clinical and commercial capacity for numerous undisclosed CAR-T therapies at its forthcoming facilities across the US, EU, and Japan. In funding news, Rubedo Life Sciences, with a focus on age-related diseases, has secured $40 million in a Series A round led by Khosla Ventures and Ahren Innovation Capital. This will expedite the company's plans to target senescent cells, particularly with its candidate RLS-1496 set to commence Phase 1 trials for atopic dermatitis and psoriasis treatments. Biosplice's lorecivivint, developed for osteoarthritis, unfortunately, did not pass its Phase 3 Clinical Trials. This failure has undoubtedly cast a shadow over the drug's approval prospects. However, Biosplice remains relentless and will continue dialogue with the FDA, sharing different trial data. In the realm of RNA-focused treatments, French biopharmaceutical firm Ipsen has signed a significant deal with Skyhawk Therapeutics, valued up to $1.8 billion. The collaboration aims to develop small molecules to alter RNA, with a focus on two rare neurological disease targets. On another front, Boehringer Ingelheim collaborates with Ochre Bio for a $35 million research partnership. This collaboration seeks to pioneer new treatments for chronic liver diseases, chiefly metabolic dysfunction-associated steatohepatitis (MASH). In a progressive partnership, Eisai and BioArctic combined their efforts in the development of a drug to cross the blood-brain barrier. This groundbreaking drug aims to fight Alzheimer's Disease and other neurodegenerative symptoms. With a financially rewarding milestoned-based agreement, BioArctic will make significant earnings as the project progresses. Lastly, an Irish biotech firm raises substantial capital – $75 million in Series B funding. This robust financial backing will launch the company into Phase 3 trials for a groundbreaking drug that can potentially cure a rare joint tumour. #pharma #biotech #topstories #biodatastudio

𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐃𝐫𝐮𝐠𝐬: 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 & 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/d7ScBhs4 The oncology drugs market is seeing unprecedented growth, driven by increasing cancer cases, innovations in targeted therapies, and strong demand for personalized treatments. Valued at $221.38 billion in 2023, it's projected to grow rapidly, reaching an impressive $525.08 billion by 2031! 📈 What’s fueling this momentum? 1️⃣ Precision Medicine: Treatments are becoming more targeted, enhancing efficacy while minimizing side effects. 2️⃣ Immuno-Oncology: Immune-based therapies are providing new hope, leveraging the body's immune system to fight cancer. 3️⃣ Innovation & Tech: AI and machine learning are fast-tracking drug discovery and clinical trials, bringing novel drugs to market faster. 4️⃣ Global Investments: Both public and private sectors are heavily investing in oncology R&D, leading to the creation of innovative and accessible therapies. 🌐 Challenges and Opportunities While the growth is promising, the industry faces hurdles like high development costs, regulatory complexities, and pricing pressures. Yet, the potential for groundbreaking discoveries and patient impact keeps this market at the forefront of pharmaceutical advancements. 🔍 Major Players Analysis Listed in this Report are: Amgen Bayer Celgene GSK ARIAD Pharmaceuticals, Inc. Eli Lilly and Company Novartis Hoffmann-La Roche Ltd. AstraZeneca Boehringer Ingelheim Pfizer Teva Pharmaceuticals #CancerTreatment #OncologyMarket #PrecisionMedicine #Pharmaceuticals #DrugDiscovery #HealthcareInnovation #OncologyDrugs #ImmunoOncology #CancerResearch #MedicalAdvancements #PharmaIndustry #LifeSciences #OncologyNews #HealthTech